98%
921
2 minutes
20
RNA-binding proteins (RBPs) play crucial roles in gene regulation. Their dysregulation has been increasingly linked to neurodegenerative diseases, liver cancer, and lung cancer. Although experimental methods like CLIP-seq accurately identify RNA-protein binding sites, they are time-consuming and costly. To address this, we propose RMDNet-a deep learning framework that integrates CNN, CNN-Transformer, and ResNet branches to capture features at multiple sequence scales. These features are fused with structural representations derived from RNA secondary structure graphs. The graphs are processed using a graph neural network with DiffPool. To optimize feature integration, we incorporate an improved dung beetle optimization algorithm, which adaptively assigns fusion weights during inference. Evaluations on the RBP-24 benchmark show that RMDNet outperforms state-of-the-art models including GraphProt, DeepRKE, and DeepDW across multiple metrics. On the RBP-31 dataset, it demonstrates strong generalization ability, while ablation studies on RBPsuite2.0 validate the contributions of individual modules. We assess biological interpretability by extracting candidate binding motifs from the first-layer CNN kernels. Several motifs closely match experimentally validated RBP motifs, confirming the model's capacity to learn biologically meaningful patterns. A downstream case study on YTHDF1 focuses on analyzing interpretable spatial binding patterns, using a large-scale prediction dataset and CLIP-seq peak alignment. The results confirm that the model captures localized binding signals and spatial consistency with experimental annotations. Overall, RMDNet is a robust and interpretable tool for predicting RNA-protein binding sites. It has broad potential in disease mechanism research and therapeutic target discovery. The source code is available https://github.com/cskyan/RMDNet .
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12247420 | PMC |
http://dx.doi.org/10.1186/s12859-025-06197-y | DOI Listing |
Anal Biochem
September 2025
School of Computer Science and Engineering, Southeast University, Nanjing 210000, China.
In the complex process of gene expression and regulation, RNA-binding proteins occupy a pivotal position for RNA. Accurate prediction of RNA-protein binding sites can help researchers better understand RNA-binding proteins and their related mechanisms. And prediction techniques based on machine learning algorithms are both cost-effective and efficient in identifying these binding sites.
View Article and Find Full Text PDFCell
September 2025
Centre for Genomic Regulation (CRG), the Barcelona Institute of Science and Technology, Dr Aiguader 88, Barcelona 08003, Spain; Universitat Pompeu Fabra, Barcelona, Spain. Electronic address:
RNA-binding proteins (RBPs) are best known as effectors along the entire gene expression pathway and as constituents of RNA-protein machines such as the ribosome and the spliceosome. Around 1,000 RBPs account for these functions in mammalian cells. The total number of RBPs has recently more than tripled to include many "well-known" proteins such as metabolic enzymes or membrane proteins, sparking debate about the biological relevance of their RNA binding.
View Article and Find Full Text PDFMethods Mol Biol
August 2025
Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina.
The respiratory syncytial virus (RSV) encodes a singular transcription antiterminator or processivity factor M. This protein ensures the adequate expression of genes toward the 5' end of the genome that results from transcription polarization, in which genes located near the 3' genomic end are expressed at much higher levels than those at the 5' end, resulting in a gradient of transcripts. Although its mechanism of action is not fully understood, it is based on its RNA-binding capacity.
View Article and Find Full Text PDFMedComm (2020)
September 2025
DP Technology Beijing China.
RNA-targeting small molecules represent a transformative frontier in drug discovery, offering novel therapeutic avenues for diseases traditionally deemed undruggable. This review explores the latest advancements in the development of RNA-binding small molecules, focusing on the current obstacles and promising avenues for future research. We highlight innovations in RNA structure determination, including X-ray crystallography, nuclear magnetic resonance spectroscopy, and cryo-electron microscopy, which provide the foundation for rational drug design.
View Article and Find Full Text PDFCurr Opin Struct Biol
August 2025
MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Crewe Rd, Edinburgh, EH4 2XU, UK. Electronic address:
In mammalian cells, RNA species make up ∼10% of chromatin by mass and play a structural role in the nucleus by acting as scaffolds and influencing genome organisation. Although many proteins bind nuclear RNAs, these interactions are often non-specific, making it challenging to define RNA's role in genome folding. Nonetheless, a clearer picture is emerging.
View Article and Find Full Text PDF